Neurotrope Company Profile (OTCMKTS:NTRP)

About Neurotrope (OTCMKTS:NTRP)

Neurotrope logoNeurotrope, Inc., formerly BlueFlash Communications, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer's disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C. It has completed Phase IIa clinical trials of Bryostatin-1 for the treatment of patients with AD.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $36.71 million
  • Outstanding Shares: 7,895,000
Average Prices:
  • 50 Day Moving Avg: $5.08
  • 200 Day Moving Avg: $7.57
  • 52 Week Range: $3.40 - $29.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.37
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.47 per share
  • Price / Book: 1.88
  • EBITDA: ($14,660,000.00)
  • Return on Equity: -57.00%
  • Return on Assets: -51.84%
  • Current Ratio: 3.45%
  • Quick Ratio: 3.45%
  • Average Volume: 31,628 shs.
  • Beta: 2.6
  • Short Ratio: 1.72

Frequently Asked Questions for Neurotrope (OTCMKTS:NTRP)

What is Neurotrope's stock symbol?

Neurotrope trades on the OTCMKTS under the ticker symbol "NTRP."

How were Neurotrope's earnings last quarter?

Neurotrope Inc (OTCMKTS:NTRP) announced its quarterly earnings data on Friday, August, 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.03. View Neurotrope's Earnings History.

Where is Neurotrope's stock going? Where will Neurotrope's stock price be in 2017?

1 equities research analysts have issued 12-month target prices for Neurotrope's stock. Their forecasts range from $31.00 to $31.00. On average, they expect Neurotrope's share price to reach $31.00 in the next year. View Analyst Ratings for Neurotrope.

Who are some of Neurotrope's key competitors?

Who are Neurotrope's key executives?

Neurotrope's management team includes the folowing people:

  • Joshua N. Silverman, Chairman of the Board
  • Daniel L Alkon M.D., President, Chief Scientific Officer
  • Susanne Wilke Ph.D., Chief Executive Officer, Director
  • William S. Singer, Vice Chairman of the Board
  • Robert Weinstein, Chief Financial Officer, Executive Vice President
  • Paula T. Trzepacz, Executive Vice President and Chief Medical Officer
  • Bruce T. Bernstein, Director
  • Kenneth J. Gorelick, Director
  • Andrew D. Perlman, Director
  • Shana Phares, Director

How do I buy Neurotrope stock?

Shares of Neurotrope can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neurotrope's stock price today?

One share of Neurotrope stock can currently be purchased for approximately $4.65.

MarketBeat Community Rating for Neurotrope (OTCMKTS NTRP)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  23 (Vote Outperform)
Underperform Votes:  18 (Vote Underperform)
Total Votes:  41
MarketBeat's community ratings are surveys of what our community members think about Neurotrope and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Neurotrope (OTCMKTS:NTRP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $31.00
Consensus Price Target History for Neurotrope (OTCMKTS:NTRP)
Price Target History for Neurotrope (OTCMKTS:NTRP)
Analysts' Ratings History for Neurotrope (OTCMKTS:NTRP)
DateFirmActionRatingPrice TargetDetails
5/2/2017AegisReiterated RatingBuy$31.00View Rating Details
(Data available from 10/22/2015 forward)


Earnings History for Neurotrope (OTCMKTS:NTRP)
Earnings by Quarter for Neurotrope (OTCMKTS:NTRP)
Earnings History by Quarter for Neurotrope (OTCMKTS NTRP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2015Q2 2015($0.08)($0.11)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.10)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Neurotrope (OTCMKTS:NTRP)
Current Year EPS Consensus Estimate: $-1.89 EPS
Next Year EPS Consensus Estimate: $-1.96 EPS


Dividend History for Neurotrope (OTCMKTS:NTRP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Neurotrope (OTCMKTS:NTRP)
Insider Ownership Percentage: 4.20%
Insider Trades by Quarter for Neurotrope (OTCMKTS:NTRP)
Institutional Ownership by Quarter for Neurotrope (OTCMKTS:NTRP)
Insider Trades by Quarter for Neurotrope (OTCMKTS:NTRP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/2/2016Bruce BernsteinDirectorBuy50,000$0.28$14,000.00View SEC Filing  
11/23/2016Kenneth J GorelickDirectorBuy5,000$0.29$1,450.00View SEC Filing  
8/26/2016Kenneth J GorelickDirectorBuy5,000$0.41$2,050.00View SEC Filing  
11/23/2015James GottliebDirectorBuy10,000$0.59$5,900.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Neurotrope (OTCMKTS:NTRP)
Latest Headlines for Neurotrope (OTCMKTS:NTRP)
Loading headlines, please wait.



Neurotrope (NTRP) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.